Semaglutide associated with lower food noise scores in two real-world telehealth studies
On November 14, 2026, Novo Nordisk presented real-world findings from the SIGNAL and OCTANE studies at ObesityWeek 2026, looking at how food noise scores changed for adults with overweight or obesity taking Wegovy injection or Wegovy pill.
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist made by Novo Nordisk and sold as Ozempic (weekly injection, type 2 diabetes), Rybelsus (daily tablet, type 2 diabetes) and Wegovy (obesity, as a weekly injection and, since December 2025 in the US and July 2026 in the EU, as a daily pill).
Read the full guide →In 30 seconds
- In SIGNAL, a random sample of 26,213 treatment-naive adults starting semaglutide injection showed an adjusted mean food noise score change from baseline of -0.42 points within the first month and -0.72 points at month 6, from an adjusted mean baseline score of 2.72.
- In OCTANE, adults starting oral semaglutide reported a statistically significant reduction of about 25% in average food noise scores over 3 months (total RAID-FN score 2.8 to 2.1, p value below 0.001).
- Both are retrospective cohort analyses of de-identified telehealth data: Novo Nordisk states that real-world studies evaluate associations and cannot determine causality.
Why it matters
The announcement defines food noise as persistent, intrusive and unwanted thoughts about food, and attributes that definition to a published paper on food noise definition, measurement and future research directions (Dhurandhar et al., Nutr Diabetes, 2025). Both studies assessed it with a validated seven-item questionnaire, the Ro Allison Indiana Dhurandhar-Food Noise Inventory (RAID-FN), which measures persistent, intrusive and unwanted thoughts about food. According to Novo Nordisk, food noise is an emerging area of research in obesity care, with real-world studies suggesting semaglutide may provide an additional patient-centered benefit beyond weight loss.
"Patients at our center often describe persistent and intrusive thoughts about food, and that managing those thoughts can take a toll on their day-to-day lives," said Louis J. Aronne, MD, Director of the Comprehensive Weight Control Center, Weill Cornell Medicine, and co-author of the studies. He added that the SIGNAL and OCTANE findings showed that semaglutide injection and oral semaglutide were associated with early reductions in food noise in real-world studies.
The details
- Both analyses are retrospective cohort analyses that used de-identified patient data from the Ro telehealth platform and a validated seven-item questionnaire, the RAID-FN, to assess food noise.
- SIGNAL is a retrospective cohort study of de-identified data from a random sample of 26,213 treatment-naive adults with obesity or overweight with at least one weight-related condition initiating semaglutide injection, followed for up to six months in a real-world telehealth setting, with initiation through the Ro telehealth platform between May 20, 2025, and June 8, 2026.
- In SIGNAL, the adjusted mean baseline RAID-FN total score was 2.72 (95% CI: 2.71, 2.74). Mean food noise scores decreased within the first month, with an adjusted mean change from baseline of -0.42 points (95% CI: -0.43, -0.41).
- In SIGNAL, the greatest reductions were observed during the first three months, and reductions were maintained through month 6, when the adjusted mean change from baseline was -0.72 points (95% CI: -0.74 to -0.70). Longitudinal changes were evaluated with a linear mixed-effects model with repeated measures, adjusted for baseline total score, demographics and clinical characteristics.
- The SIGNAL description states that food noise was measured using the validated RAID-FN questionnaire, which consists of 7 items rated from 1 to 5, with 5 indicating the highest food noise intensity.
- OCTANE included 7,669 adults with overweight or obesity, with or without prior weight-management treatment experience, who initiated oral semaglutide between January 5 and February 7, 2026. Adults initiating oral semaglutide reported a statistically significant reduction in average food noise scores over 3 months, reducing by about 25% from baseline (total RAID-FN score 2.8 to 2.1, p<0.001).
- In OCTANE, food noise change at baseline and 3 months was reported by 6,180 patients, and treatment improvement at 3 months was reported by 6,638 patients.
- At three months in OCTANE, 86.4% reported at least one treatment improvement, including better-fitting clothing (67.5%), healthier eating (51.6%), more physical activity (26.8%), more energy during the day (26.6%), improved mood (21.7%), fewer alcohol cravings (18.8%) and better sleep (18.6%).
- At program entry, participants' most commonly reported treatment goals were to lose weight (98.0%), improve general physical health (76.5%), and increase confidence in their appearance (54.5%). The announcement places this sentence among the OCTANE figures but attaches it to the SIGNAL reference, so which study it describes is not clear.
- SIGNAL participants were included if they reported RAID-FN and weight data at baseline and at least one monthly timepoint and remained persistent on treatment, defined as no treatment gap longer than 30 days. OCTANE participants also remained persistent on treatment for three months under the same definition.
- Novo Nordisk notes that the named strengths of semaglutide injection and semaglutide tablets contain a Boxed Warning for possible thyroid tumors, including cancer, and should not be used in those with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The announcement attaches that warning to those two named product strengths, not to semaglutide in general.
What it does not change
These are observational analyses, not approvals and not randomized trials. Novo Nordisk states that real-world evidence can complement randomized controlled trials, which are the gold standard for evaluating a treatment's safety and efficacy, and that real-world studies evaluate associations and cannot determine causality. Neither analysis reported a placebo or comparator group. The company also lists limitations of SIGNAL and OCTANE: variable timing and completeness of data being collected during routine telehealth care, potential bias associated with self-reported data, possible selection bias resulting from the treatment-persistence requirement, and limited generalizability to the broader population.
What's next
Both analyses were presented at ObesityWeek 2026 in Washington, DC, part of 26 Novo Nordisk abstracts announced for the congress. On the research agenda, Louis J. Aronne, MD, said that looking forward, additional research can help clarify the clinical relevance of such food noise and its place in everyday obesity care. Michelle Skinner Moore, PharmD, MBA, interim head of clinical development, medical and regulatory affairs and vice president, medical affairs at Novo, said that while food noise remains an emerging area of research, the company is working to advance the science of obesity and broaden understanding beyond changes on the scale.
What we don't know yet
The clinical relevance of the reported food noise score changes is not established in the announcement, which presents food noise as an emerging area of research. SIGNAL assessed food noise scores and weight at baseline and over six months of follow-up, but the announcement reports no weight results alongside the food noise figures. Because the analyses are observational and based on self-reported data from one telehealth platform, they cannot show that semaglutide caused the changes, and the company notes limited generalizability to the broader population. No head to head comparison between semaglutide injection and oral semaglutide is reported.
Products sold online as research peptides are not the medicines studied or approved in this news. A medicine is available in a country only after that country's medicines agency approves it.
Source documents
This article reports news for information only. It is not medical or legal advice and does not recommend any use or dose. Every fact comes from the source documents listed above.